Published in Front Aging Neurosci on May 18, 2017
Chiglitazar Added to Metformin for Type 2 Diabetes | NCT04807348
Mild cognitive impairment: clinical characterization and outcome. Arch Neurol (1999) 33.06
An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage (2006) 25.52
A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans Med Imaging (1998) 23.54
A hybrid approach to the skull stripping problem in MRI. Neuroimage (2004) 9.59
Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol (2001) 8.88
Automated manifold surgery: constructing geometrically accurate and topologically correct models of the human cerebral cortex. IEEE Trans Med Imaging (2001) 8.14
Comparing predictors of conversion and decline in mild cognitive impairment. Neurology (2010) 5.69
Mild cognitive impairment: ten years later. Arch Neurol (2009) 5.02
MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain (2009) 4.51
Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain (2010) 4.39
Geometrically accurate topology-correction of cortical surfaces using nonseparating loops. IEEE Trans Med Imaging (2007) 4.18
Spatial patterns of brain atrophy in MCI patients, identified via high-dimensional pattern classification, predict subsequent cognitive decline. Neuroimage (2007) 4.07
Predictive markers for AD in a multi-modality framework: an analysis of MCI progression in the ADNI population. Neuroimage (2010) 3.58
Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol (2010) 3.46
Using voxel-based morphometry to map the structural changes associated with rapid conversion in MCI: a longitudinal MRI study. Neuroimage (2005) 3.28
Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in MCI and AD: A study of the ADNI cohort. Neuroimage (2010) 3.27
Prediction of MCI to AD conversion, via MRI, CSF biomarkers, and pattern classification. Neurobiol Aging (2010) 3.16
Longitudinal pattern of regional brain volume change differentiates normal aging from MCI. Neurology (2009) 2.84
Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol (2012) 2.84
White matter changes in mild cognitive impairment and AD: A diffusion tensor imaging study. Neurobiol Aging (2005) 2.79
Principal component analysis based on l1-norm maximization. IEEE Trans Pattern Anal Mach Intell (2008) 2.57
Loss of connectivity in Alzheimer's disease: an evaluation of white matter tract integrity with colour coded MR diffusion tensor imaging. J Neurol Neurosurg Psychiatry (2000) 2.55
FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. Eur J Nucl Med Mol Imaging (2009) 2.15
Relationships between hippocampal atrophy, white matter disruption, and gray matter hypometabolism in Alzheimer's disease. J Neurosci (2008) 2.15
Boosting power for clinical trials using classifiers based on multiple biomarkers. Neurobiol Aging (2010) 2.13
MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults. Neurology (2011) 2.08
CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. Neurobiol Aging (2006) 1.91
Combining MRI and CSF measures for classification of Alzheimer's disease and prediction of mild cognitive impairment conversion. Neuroimage (2012) 1.87
Identification of conversion from mild cognitive impairment to Alzheimer's disease using multivariate predictors. PLoS One (2011) 1.66
Large-scale functional brain network abnormalities in Alzheimer's disease: insights from functional neuroimaging. Behav Neurol (2009) 1.58
Discriminant analysis of longitudinal cortical thickness changes in Alzheimer's disease using dynamic and network features. Neurobiol Aging (2011) 1.55
Four subgroups of Alzheimer's disease based on patterns of atrophy using VBM and a unique pattern for early onset disease. Neuroimage (2006) 1.40
Impact of APOE in mild cognitive impairment. Neurology (2004) 1.37
The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI). Front Aging Neurosci (2013) 1.26
Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. Eur J Nucl Med Mol Imaging (2012) 1.19
Conversion from mild cognitive impairment to probable Alzheimer's disease predicted by brain magnetic resonance spectroscopy. Am J Psychiatry (2005) 1.19
Sparse Multi-Task Regression and Feature Selection to Identify Brain Imaging Predictors for Memory Performance. Proc IEEE Int Conf Comput Vis (2011) 1.17
Prediction of Alzheimer's disease in subjects with mild cognitive impairment from the ADNI cohort using patterns of cortical thinning. Neuroimage (2012) 1.17
Mild cognitive impairment: baseline and longitudinal structural MR imaging measures improve predictive prognosis. Radiology (2011) 1.13
Sulcal morphology changes and their relationship with cortical thickness and gyral white matter volume in mild cognitive impairment and Alzheimer's disease. Neuroimage (2008) 1.11
Mild cognitive impairment (MCI) represents early-stage Alzheimer's disease. J Alzheimers Dis (2005) 1.10
Genetic, structural and functional imaging biomarkers for early detection of conversion from MCI to AD. Med Image Comput Comput Assist Interv (2012) 1.08
Diagnostic accuracy of 18 F-FDG and 11 C-PIB-PET for prediction of short-term conversion to Alzheimer's disease in subjects with mild cognitive impairment. Int J Clin Pract (2012) 1.04
How early can we predict Alzheimer's disease using computational anatomy? Neurobiol Aging (2013) 1.01
Longitudinal cerebrospinal fluid biomarkers over four years in mild cognitive impairment. J Alzheimers Dis (2012) 0.99
Apo-Eε4 allele in conjunction with Aβ42 and tau in CSF: biomarker for Alzheimer's disease. Curr Alzheimer Res (2011) 0.95
CSF p-Tau levels in the prediction of Alzheimer's disease. Biol Open (2013) 0.94
Robust image analysis with sparse representation on quantized visual features. IEEE Trans Image Process (2012) 0.94
Conversion to dementia in mild cognitive impairment is associated with decline of N-actylaspartate and creatine as revealed by magnetic resonance spectroscopy. Psychiatry Res (2009) 0.92
Aberrant intra- and inter-network connectivity architectures in Alzheimer's disease and mild cognitive impairment. Sci Rep (2015) 0.89
Evaluating Alzheimer's disease progression using rate of regional hippocampal atrophy. PLoS One (2013) 0.87
Measurements of medial temporal lobe atrophy for prediction of Alzheimer's disease in subjects with mild cognitive impairment. Neurobiol Aging (2013) 0.87
Magnetic resonance spectroscopy as a predictor of conversion of mild cognitive impairment to dementia. J Neurol Sci (2013) 0.86
Disrupted structural and functional brain connectomes in mild cognitive impairment and Alzheimer's disease. Neurosci Bull (2014) 0.84
Comparison of cortical thickness in patients with early-stage versus late-stage amnestic mild cognitive impairment. Eur J Neurol (2013) 0.83
Detection of volume loss in hippocampal layers in Alzheimer's disease using 7 T MRI: a feasibility study. Neuroimage Clin (2014) 0.82
Advances in high-field magnetic resonance spectroscopy in Alzheimer's disease. Curr Alzheimer Res (2014) 0.82
¹⁸F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev (2015) 0.80
Correlation of hippocampal volume and cognitive performances in patients with either mild cognitive impairment or Alzheimer's disease. CNS Neurosci Ther (2014) 0.80
Toward systems neuroscience in mild cognitive impairment and Alzheimer's disease: a meta-analysis of 75 fMRI studies. Hum Brain Mapp (2014) 0.79
Disrupted topological organization of resting-state functional brain network in subcortical vascular mild cognitive impairment. CNS Neurosci Ther (2015) 0.78
Structural and functional brain changes in the default mode network in subtypes of amnestic mild cognitive impairment. J Geriatr Psychiatry Neurol (2014) 0.78
Patterns of (11)C-PIB cerebral retention in mild cognitive impairment patients. Rev Esp Med Nucl Imagen Mol (2015) 0.77
Various MRS application tools for Alzheimer disease and mild cognitive impairment. AJNR Am J Neuroradiol (2014) 0.77
Improving CSF Biomarkers' Performance for Predicting Progression from Mild Cognitive Impairment to Alzheimer's Disease by Considering Different Confounding Factors: A Meta-Analysis. Front Aging Neurosci (2014) 0.77
Magnetic resonance spectroscopy in the prediction of early conversion from amnestic mild cognitive impairment to dementia: a prospective cohort study. BMJ Open (2011) 0.76
Dimensionality reduced cortical features and their use in predicting longitudinal changes in Alzheimer's disease. Neurosci Lett (2013) 0.76
Brain atrophy rates in first degree relatives at risk for Alzheimer's. Neuroimage Clin (2014) 0.76
Prediction of conversion from amnestic mild cognitive impairment to Alzheimer's disease using proton magnetic resonance spectroscopy. Rinsho Shinkeigaku (2015) 0.76
SORL1 Gene is Associated with the Conversion from Mild Cognitive Impairment to Alzheimer's Disease. J Alzheimers Dis (2015) 0.76
Topography of cortical thinning areas associated with hippocampal atrophy (HA) in patients with Alzheimer's disease (AD). Arch Gerontol Geriatr (2011) 0.75
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol (2009) 14.42
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain (2009) 7.20
Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain (2008) 6.29
Comparing predictors of conversion and decline in mild cognitive impairment. Neurology (2010) 5.69
Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol (2010) 5.53
Multimodal classification of Alzheimer's disease and mild cognitive impairment. Neuroimage (2011) 5.24
Protective variant for hippocampal atrophy identified by whole exome sequencing. Ann Neurol (2015) 5.10
MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain (2009) 4.51
Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain (2010) 4.39
Automatic classification of patients with Alzheimer's disease from structural MRI: a comparison of ten methods using the ADNI database. Neuroimage (2010) 4.28
Relationships between biomarkers in aging and dementia. Neurology (2009) 4.16
Spatial patterns of brain atrophy in MCI patients, identified via high-dimensional pattern classification, predict subsequent cognitive decline. Neuroimage (2007) 4.07
Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging (2009) 3.97
The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement (2010) 3.85
Identification of common variants associated with human hippocampal and intracranial volumes. Nat Genet (2012) 3.73
MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology (2009) 3.72
Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology (2012) 3.58
Multi-modal multi-task learning for joint prediction of multiple regression and classification variables in Alzheimer's disease. Neuroimage (2011) 3.47
Tensor-based morphometry as a neuroimaging biomarker for Alzheimer's disease: an MRI study of 676 AD, MCI, and normal subjects. Neuroimage (2008) 3.40
The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement (2010) 3.30
Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in MCI and AD: A study of the ADNI cohort. Neuroimage (2010) 3.27
Fast and robust multi-atlas segmentation of brain magnetic resonance images. Neuroimage (2009) 3.13
Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans. Alzheimers Dement (2010) 3.11
Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch Neurol (2012) 3.03
Alzheimer disease: quantitative structural neuroimaging for detection and prediction of clinical and structural changes in mild cognitive impairment. Radiology (2009) 2.90
Update on the magnetic resonance imaging core of the Alzheimer's disease neuroimaging initiative. Alzheimers Dement (2010) 2.88
Hippocampal atrophy as a quantitative trait in a genome-wide association study identifying novel susceptibility genes for Alzheimer's disease. PLoS One (2009) 2.85
Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol (2012) 2.84
Evidence for ordering of Alzheimer disease biomarkers. Arch Neurol (2011) 2.83
MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology (2009) 2.83
Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Neuroimage (2009) 2.80
Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: Genetics core aims, progress, and plans. Alzheimers Dement (2010) 2.79
Voxelwise genome-wide association study (vGWAS). Neuroimage (2010) 2.69
Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimers Dement (2010) 2.68
Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease. AJNR Am J Neuroradiol (2010) 2.61
Automated MRI measures identify individuals with mild cognitive impairment and Alzheimer's disease. Brain (2009) 2.61
Early diagnosis of Alzheimer's disease using cortical thickness: impact of cognitive reserve. Brain (2009) 2.51
Longitudinal change of biomarkers in cognitive decline. Arch Neurol (2011) 2.51
Bias in tensor based morphometry Stat-ROI measures may result in unrealistic power estimates. Neuroimage (2011) 2.50
Spatially augmented LPboosting for AD classification with evaluations on the ADNI dataset. Neuroimage (2009) 2.47
Automatic quality assessment in structural brain magnetic resonance imaging. Magn Reson Med (2009) 2.43
Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol (2011) 2.41
3D characterization of brain atrophy in Alzheimer's disease and mild cognitive impairment using tensor-based morphometry. Neuroimage (2008) 2.40
Subregional neuroanatomical change as a biomarker for Alzheimer's disease. Proc Natl Acad Sci U S A (2009) 2.37
Automated cross-sectional and longitudinal hippocampal volume measurement in mild cognitive impairment and Alzheimer's disease. Neuroimage (2010) 2.32
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement (2013) 2.32
Multi-modal imaging predicts memory performance in normal aging and cognitive decline. Neurobiol Aging (2008) 2.31
Validation of a fully automated 3D hippocampal segmentation method using subjects with Alzheimer's disease mild cognitive impairment, and elderly controls. Neuroimage (2008) 2.30
Ventricular enlargement as a possible measure of Alzheimer's disease progression validated using the Alzheimer's disease neuroimaging initiative database. Brain (2008) 2.28
Optimizing power to track brain degeneration in Alzheimer's disease and mild cognitive impairment with tensor-based morphometry: an ADNI study of 515 subjects. Neuroimage (2009) 2.28
Automated 3D mapping of hippocampal atrophy and its clinical correlates in 400 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls. Hum Brain Mapp (2009) 2.28
Discovering genetic associations with high-dimensional neuroimaging phenotypes: A sparse reduced-rank regression approach. Neuroimage (2010) 2.27
Automated mapping of hippocampal atrophy in 1-year repeat MRI data from 490 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls. Neuroimage (2008) 2.25
Structural MRI biomarkers for preclinical and mild Alzheimer's disease. Hum Brain Mapp (2009) 2.24
Bias in estimation of hippocampal atrophy using deformation-based morphometry arises from asymmetric global normalization: an illustration in ADNI 3 T MRI data. Neuroimage (2009) 2.22
Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology (2010) 2.20
Regional rates of neocortical atrophy from normal aging to early Alzheimer disease. Neurology (2009) 2.18
CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer's disease. J Neurosci (2010) 2.18
Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Ann Neurol (2010) 2.16
Boosting power for clinical trials using classifiers based on multiple biomarkers. Neurobiol Aging (2010) 2.13
A commonly carried allele of the obesity-related FTO gene is associated with reduced brain volume in the healthy elderly. Proc Natl Acad Sci U S A (2010) 2.12
Statistical analysis of longitudinal neuroimage data with Linear Mixed Effects models. Neuroimage (2012) 2.11
LEAP: learning embeddings for atlas propagation. Neuroimage (2009) 2.09
The Alzheimer's Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes. Alzheimers Dement (2010) 2.09
MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults. Neurology (2011) 2.08
Alzheimer's disease neuroimaging initiative: a one-year follow up study using tensor-based morphometry correlating degenerative rates, biomarkers and cognition. Neuroimage (2009) 2.03
Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology (2014) 2.03
Multidimensional classification of hippocampal shape features discriminates Alzheimer's disease and mild cognitive impairment from normal aging. Neuroimage (2009) 1.95
Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative. Arch Gen Psychiatry (2011) 1.94
Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative. Arch Neurol (2010) 1.94
Genome-wide analysis reveals novel genes influencing temporal lobe structure with relevance to neurodegeneration in Alzheimer's disease. Neuroimage (2010) 1.94
Genome-wide association study of Alzheimer's disease. Transl Psychiatry (2012) 1.88
Estimating the age of healthy subjects from T1-weighted MRI scans using kernel methods: exploring the influence of various parameters. Neuroimage (2010) 1.87
Hippocampal atrophy rates and CSF biomarkers in elderly APOE2 normal subjects. Neurology (2010) 1.86
Ensemble sparse classification of Alzheimer's disease. Neuroimage (2012) 1.84
Nonlinear registration of longitudinal images and measurement of change in regions of interest. Med Image Anal (2011) 1.82
Brain atrophy in healthy aging is related to CSF levels of Aβ1-42. Cereb Cortex (2010) 1.79
The dynamics of cortical and hippocampal atrophy in Alzheimer disease. Arch Neurol (2011) 1.79
Multi-method analysis of MRI images in early diagnostics of Alzheimer's disease. PLoS One (2011) 1.79
Unbiased tensor-based morphometry: improved robustness and sample size estimates for Alzheimer's disease clinical trials. Neuroimage (2012) 1.76
Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative. Arch Neurol (2011) 1.75
Abnormal cortical networks in mild cognitive impairment and Alzheimer's disease. PLoS Comput Biol (2010) 1.72
BEaST: brain extraction based on nonlocal segmentation technique. Neuroimage (2011) 1.72
Regional shape abnormalities in mild cognitive impairment and Alzheimer's disease. Neuroimage (2009) 1.71
Robust atrophy rate measurement in Alzheimer's disease using multi-site serial MRI: tissue-specific intensity normalization and parameter selection. Neuroimage (2009) 1.71
Random forest-based similarity measures for multi-modal classification of Alzheimer's disease. Neuroimage (2012) 1.71
3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. Neurobiol Aging (2010) 1.70
Mapping Alzheimer's disease progression in 1309 MRI scans: power estimates for different inter-scan intervals. Neuroimage (2010) 1.69
Identifying quantitative trait loci via group-sparse multitask regression and feature selection: an imaging genetics study of the ADNI cohort. Bioinformatics (2011) 1.69
Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer's disease. Proc Natl Acad Sci U S A (2010) 1.68
Multi-source feature learning for joint analysis of incomplete multiple heterogeneous neuroimaging data. Neuroimage (2012) 1.66
Identification of conversion from mild cognitive impairment to Alzheimer's disease using multivariate predictors. PLoS One (2011) 1.66
Selective disruption of the cerebral neocortex in Alzheimer's disease. PLoS One (2010) 1.65
Fully automatic hippocampus segmentation and classification in Alzheimer's disease and mild cognitive impairment applied on data from ADNI. Hippocampus (2009) 1.65
Improving intersubject image registration using tissue-class information benefits robustness and accuracy of multi-atlas based anatomical segmentation. Neuroimage (2010) 1.65
Does feature selection improve classification accuracy? Impact of sample size and feature selection on classification using anatomical magnetic resonance images. Neuroimage (2011) 1.64
Predicting future clinical changes of MCI patients using longitudinal and multimodal biomarkers. PLoS One (2012) 1.64
Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid. Ann Neurol (2013) 1.63